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The health consequences and fiscal burden of
musculoskeletal diseases has been acknowledged but
never fully addressed. An agenda unveiled by the
World Health Organization to redress the balance sets
specific goals for the next 10 years (the bone and joint
decade). These include a 25% reduction in the
expected increase in morbidity from rheumatoid
arthritis, osteoporosis, and osteoarthritis.
Methods
We have reviewed advances in rheumatology that can
be easily integrated into routine clinical practice and
highlighted areas where appropriate treatment has
been shown to prevent later disability or morbidity.
References are supplied for published trials and
systematic reviews.
Osteoarthritis
The chronic disease model of illness advocates patients
as managers of their disease. In a trial to assess this
model in 211 patients with osteoarthritis of the knee,
Mazzuca et al reported greater benefits over one year in
a self care group compared with standard treatment.1
Diet
Cross sectional studies and studies of longitudinal
cohorts have shown that obesity increases the risk of
osteoarthritis of the knee in both men and women,2
primarily by increasing forces across the knee. An
imbalance of growth factors affecting the cartilage and
underlying bone may also contribute. Weight loss
reduces symptoms as well as improving functional
ability.3 High vitamin C intake is associated with a
threefold reduction in progression of osteoarthritis of
the knee.4 Progression of osteoarthritis of the knee and
hip is faster in people with lower vitamin D concentra›
tions.5 6 However, as yet there is no evidence that
vitamin supplementation improves symptoms.
Physical activity
Previous knee surgery and injury are risk factors for
osteoarthritis of the knee, as are occupational kneeling
and squatting. Observations in the Framingham heart
cohort confirm that heavy physical occupational and
leisure activity, particularly in obese people, predispose
to subsequent osteoarthritis of the knee.7
Coordinated joint movement requires integration
of afferent nerves from muscle intrafusal fibres and
receptors for joint proprioception. It is not known if
impaired input from both is a cause or consequence of
osteoarthritis of the knee. Exercise based rehabilitation
may improve neuromuscular control. Reduced pain
and improved function and quality of life were found
after exercises to strengthen quadriceps.8 9
Complementary therapies
Chondroitin and glucosamine are marketed as food
supplements and have been advocated for joint pain in
the media. The absence of side effects makes them
attractive therapies. A meta›analysis showed short term
evidence of benefit,10 and a three year randomised pla›
cebo controlled trial found less radiographic progres›
sion of osteoarthritis of the knee in people taking
glucosamine.11
Several studies report improvement in symptoms
from acupuncture as adjuvant therapy for osteoarthri›
tis of the knee.12 Although these studies did not use a
placebo group, this criticism applies equally to trials of
many elective surgical procedures.
Non›steroidal anti›inflammatory drugs
Non›steroidal anti›inflammatory drugs are the most
commonly prescribed drugs in the management of
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rheumatic disease. Gastrointestinal ulcers occur in
15›20% of patient taking non›steroidal anti›
inflammatories, 70% of them in the stomach. Around
2›4% of patients develop ulcer related complications,
mainly bleeding and perforation. Women, especially
those aged over 70 years with coexisting cardiac
disease and previous peptic ulcers, are at greatest risk.
These risk factors are additive.
Options to prevent complications include H2
receptor antagonists, proton pump inhibitors, and
misoprostol. More recently, selective and specific cyclo›
oxygenase›2 inhibitors have become available. A two
part comparative study of omeprazole and misoprostol
in patients taking non›steroidal anti›inflammatory
drugs found that omeprazole healed more gastric and
duodenal ulcers than misoprostol. In the maintenance
phase omeprazole prevented more duodenal ulcers
than misoprostol but not gastric ulcers. No comment
on ulcer related complications can be made.13
Two cyclo›oxygenase isoforms are recognised:
cyclo›oxygenase›1 is fundamental to normal function
(expressed in the gastrointestinal tract, kidneys, and
platelets), whereas cyclo›oxygenase›2 is induced
during inflammation. Two specific cyclo›oxygenase›2
inhibitors are currently available, rofecoxib (licensed
for osteoarthritis only) and celecoxib (licensed for
osteoarthritis and rheumatoid arthritis). Both are as
effective as conventional non›steroidal anti›
inflammatory drugs in arthritic patients.14 15 Dyspepsia
occurs in similar numbers of patients as with
conventional non›steroidal anti›inflammatories. The
incidence of endoscopic ulcer with cyclo›oxygenase›2
inhibitors, however, is similar to that in the placebo
group.
To examine the issue of ulcer related complica›
tions, Langman et al conducted a pooled analysis of
eight studies comparing conventional non›steroidal
anti›inflammatory drugs with placebo and rofecoxib in
patients with osteoarthritis (total sample size, 5435).16
Although the number of complications (perforation,
painful ulcer, and bleeding) was small, fewer arose with
rofecoxib than with other non›steroidals (ibuprofen
and diclofenac; no complications were attributed to
nabumetone but numbers treated were small).16
Rheumatoid arthritis
Early disease modifying antirheumatic treatment
improves subjective and objective markers of severity
of rheumatoid arthritis—that is, joint pain, swelling, and
tenderness; duration and severity of morning stiffness;
patient wellbeing and function; and inflammatory
markers such as erythrocyte sedimentation rate and C
reactive protein. Early treatment also improves
outcome measures such as disability, quality of life, and
radiological progression.17
Advances have focused on defining when treat›
ment should begin, how long to continue, if one drug is
better than others, if combinations confer additional
benefit, and the evidence for the more expensive
biological drugs. The double edged sword of oral
corticosteroid treatment remains under scrutiny 50
years after its introduction by Hench et al.18
When should treatment be started?
Four recent studies emphasised the importance of
early treatment for maximum benefit and to reduce
future disability. Two retrospective analyses showed
patients treated early were more likely to maintain vital
functional benefit at five years.19 20 An open ran›
domised controlled trial in 238 consecutive patients
allocated to immediate or delayed introduction of dis›
ease modifying treatment found that the group given
immediate treatment had significant advantages in
functional disability, patient score, and radiological
progression at one year.21 The fourth study in 199
patients reported better pain and physical outcomes at
three years for patients given early treatment
compared with patients in whom treatment was
delayed for nine months.22
Is it necessary to continue treatment once a
response is achieved?
A study of 285 patients who had shown a sustained
response to disease modifying treatment over five years
found that more flares occurred in the group
randomised to placebo than in those who continued
the drug over one year.23 This finding was confirmed by
a study that randomised 112 patients to treatment or
placebo. Flares occurred in 42 patients, 33 of whom
were in the placebo group. Fifty two people refused to
participate because they did not wish to be exposed to
the chance of receiving placebo.24 These results shows
that treatment is effective, of greater benefit if
introduced early, and needs to be sustained indefinitely.
Which drug to use? How much benefit should be
expected?
Sulfasalazine and methotrexate are widely used anchor
drugs. Intramuscular gold and penicillamine are more
toxic than the other drugs, and hydroxychloroquine
and auranofin confer less benefit. The future roles of
leflunomide (a recently introduced immunomodula›
tory drug that inhibits synthesis of pyrimidine and has
a similar benefit to sulfasalazine and methotrexate)25
and minocycline (effective in rheumatoid arthritis but
not licensed) have yet to be established. Concerns
about long term cumulative toxicity with systemic
corticosteroids and the short term relief of symptoms
(average nine months) has limited their widespread
use, despite favourable radiological data.26 In the com›
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bination study by Boers et al, the dose of corticosteroid
(60 mg) was too high to be maintained without
unacceptable toxicity.27
Along with drugs against tumour necrosis factor á,
the choice of antirheumatic drugs is now wider. Thus
all patients with rheumatoid arthritis should have
access to an effective drug early in the course of their
disease. A 50% improvement in symptoms and acute
phase reactants should be achieved.
Targeted immunotherapy
Tumour necrosis factor á, a product of macrophages,
acts on the immune system to induce the production of
other pro›inflammatory mediators. Two drugs that
inhibit tumour necrosis factor activity have recently
been licensed for treatment of rheumatoid arthritis,
infliximab and etanercept. Infliximab is a chimeric
monoclonal antibody given as an intravenous infusion
at 0, 2, and 6 weeks and then every 8 weeks. Infliximab
cross links tumour necrosis factor bound to T cells,
thus inactivating or destroying it. A double blind study
of infliximab in addition to methotrexate showed con›
siderable benefit. Side effects include short lived early
and late infusion reactions. One patient receiving
infliximab died of infection during the study.28
Etanercept is a tumour necrosis factor receptor
fusion protein designed to bind circulatory tumour
necrosis factor á. It is given as a subcutaneous injection
of 25 mg twice weekly, either alone or with methotrex›
ate. Results from placebo controlled studies are
encouraging.29 Although no major complications were
seen in clinical trials, serious and fatal infections have
been reported during postmarketing surveillance in
the United States.
Current limitations of treatment
There are concerns that continued inhibition of
pro›inflammatory molecules may increase the risk of
infection and cancer, particularly lymphoproliferative
malignancies. Currently there is no such evidence.
Unless these drugs prove more effective than existing
treatments, their greater costs may preclude wide›
spread early use.
Osteoporosis
Osteoporosis is an important health problem in
Western nations, and the ageing population is likely to
exacerbate the problem.30 An estimated 75 million peo›
ple in Europe, the United States, and Japan are affected
by osteoporosis. The resultant fractures have associated
economic costs and a substantial impact on quality of
life. Vertebral and hip fractures are associated with
extensive morbidity and premature mortality. Indeed,
even the fear of falling in older women affects wellbeing;
recognition that osteoporotic fractures often lead to loss
of ability to live independently has a detrimental effect
on quality of life.
Who to target?
A third of women and one in eight men will sustain an
osteoporotic fracture. In childhood adequate diet and
weight bearing exercise are essential to achieve optimal
peak bone mass. The box lists some of the actions that
can be taken by adults to prevent osteoporosis.
The patients most in need of assessment can be
fairly readily identified: those who have sustained a low
impact Colles’ or other fracture are at increased risk of
subsequent serious osteoporotic fracture. Other risk
factors include smoking, low weight (body mass index
< 19), early menopause, immobility, corticosteroid
treatment, and maternal family history.
An audit found that most patients who have an
osteoporotic fracture are not started on treatment for
secondary prevention of osteoporosis.31 Recent guide›
lines on the prevention and management of cortico›
steroid induced osteoporosis have outlined a practical
approach for this group of patients.32
Range of treatments
Prophylaxis against osteoporosis needs to be contin›
ued long term. The side effects and method of admin›
istration must therefore be acceptable to the patient if
compliance is to be optimal. Thus the increasing range
of treatments and the greater acceptability of these
options are important. These include “no bleed”
hormone replacement therapy and selective oestrogen
receptor modulators.33 Selective oestrogen receptor
modulators do not increase the risk of breast cancer
and may prove protective. A wider range of
bisphosphonates is available (with alendronate show›
ing particular benefit in relation to femoral neck
fracture),34 but gastrointestinal intolerance poses a
problem.35 More palatable calcium and vitamin D
preparations with appropriate doses of each have been
formulated. Supplementation has been shown to
reduce hip fractures in elderly people36 and is also
advisable in patients with low calcium intake and
evidence of osteoporosis. Many millions of patients
have the potential to benefit from an appropriate osteo›
porosis prevention strategy.
The recent observation that inhibition of
hydroxymethylglutaryl coenzyme A reductase may
reduce the risk of fracture raises the possibility that
patients requiring statin for cardiovascular disease may
derive additional benefit in terms of osteoporosis.37
Competing interests: None declared.
Osteoporosis: what can the patient do?
Stop smoking
Exercise—Weight bearing exercise improves bone
density, and activities such as swimming are important
in maintaining mobility and preventing falls
Diet—An adequate calcium intake (1000 mg till age 60,
1500 mg thereafter)
Ongoing research studies
Osteoarthritis: effects of glucosamine and chondroitin
on outcome (National Institutes of Health study)
Non›steroidal anti›inflammatory drugs: do
cyclo›oxygenase›2 selective drugs reduce
gastrointestinal toxicity in “true to life” setting?
Rheumatoid arthritis:
Value of combination treatments
Role of targeted immunotherapy
Osteoporosis:
New methods of delivery of bisphosphonates
including nasal inhalation
Role of combination treatments
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A memorable patient
All in a day’s work
At 82 she was still a beautiful woman. Her numerous medical
problems and her elbow crutch did not diminish her elegance
and her speech, polished by some high class English boarding
school for girls as well as the years spent being the gracious
hostess at colonial garden parties.
I gradually got round to the reason for her seeing me for a
cardiological opinion. Chest pain? Well, yes, particularly on hills.
But I needed to know the extent to which she might be limited
around the house. I asked my usual question, “What would be the
heaviest thing you would do in an ordinary day at home?”
There was a pause during which I seemed to hear the regular
gentle swish of the punkah and the steady buzzing of the cicadas
in the sandalwood trees. “I suppose it is when I carry my tortoises
about.”
There was a moment or two while my imagination raced. I tried
a nonchalant, “And how much would a tortoise weigh, may I ask?”
“Well Stanley is 21 pounds, while Cynthia is rather less as she had
to have some facial surgery after a mishap with a lawn mower.”
It was all terribly British. Not a smile cracked. At the end she
said, “I do hope you might come and meet Stanley and Cynthia
sometime.”
Honours come no higher.
(The names of the tortoises have been changed.)
Edwin R Nye physician, Dunedin, New Zealand
We welcome articles of up to 600 words on topics such as A
memorable patient, A paper that changed my practice,My most
unfortunate mistake, or any other piece conveying instruction,
pathos, or humour. If possible the article should be supplied on a
disk. Permission is needed from the patient or a relative if an
identifiable patient is referred to. We also welcome contributions
for “Endpieces,” consisting of quotations of up to 80 words (but
most are considerably shorter) from any source, ancient or
modern, which have appealed to the reader.
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